| Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease -> Monitor Keywords |
|
|
  Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung diseaseUSPTO Application #: 20070178073Title: Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease Abstract: The present invention relates to a composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease, more precisely a composition containing separated or proliferated cells from umbilical cord blood for intratracheal administration for treating developmental and/or chronic lung disease. The cells of the composition of the present invention have excellent activities of proliferation and differentiation, so that the extraction, separation and selection of a tissue donor are all very easy. Besides, the composition of the invention can be very effectively used for the treatment of developmental and/or chronic diseases by intratracheal administration. (end of abstract)
Agent: Greenlee Winner And Sullivan P C - Boulder, CO, US USPTO Applicaton #: 20070178073 - Class: 424 937 (USPTO) The Patent Description & Claims data below is from USPTO Patent Application 20070178073. Brief Patent Description - Full Patent Description - Patent Application Claims
TECHNICAL FIELD [0001]The present invention relates to a composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease, more precisely a composition containing separated or proliferated cells from umbilical cord blood for intratracheal administration for treating developmental and/or chronic lung disease. BACKGROUND ART [0002]The developmental and/or chronic lung disease includes adult chronic obstructive lung disease (COPD) such as cystic fibrosis, emphysema, and bronchopulmonary dysplasia of infant or premature baby, etc. The seriousness of these diseases is that there is no specific treatment modality even though the severeness and chronicity of these diseases cannot be disregarded. The bronchopulmonary dysplasia is a chronic lung disease developed during the treatment of respiratory failure in a newborn infant or a premature baby. Recent progress of treating a premature baby increases the incidence of this untreatable disease (Avery M E et al., Pediatrics 79: 26-30, 1987). Not only this disease is regarded as a major cause of death of a newborn infant or a premature baby, but also among survivors, long-term hospitalization is required and serious side effects including pulmonary hypertension must be a worry. Even after discharge from hospital, re-hospitalization rate of bronchopulmonary dysplasia infants is usaually more than 50% because they are more susceptible for acute viral bronchiolitis and pneumonia, and various infectious problems. It is also known that bronchopulmonary dysplasia might be progressed to bronchial asthma because of continuous bronchial hyper-sesntivity (Coalson J J. Semin Neonatol, 8:73-81, 2003) and associated with a serious long-term neurodevelopmental sequalae such as cerebral palsy (Bregman J and Farrell E E, Clin Perinatol, 19: 673-94, 1992). [0003]An effective treatment method for bronchopulmonary dysplasia has not been developed, yet. It has been a major approach for the treatment of bronchopulmonary dysplasia to reduce barotrauma or volutrauma caused by positive pressure ventilation or reduce oxygen concentration during the artificial ventilation for a new born- and a premature baby. In addition, steroid has been used to prevent and/or treat inflammation in the damaged lung. However, steroid treatment is now limited in relation to the recent reports that the use of steroid might be responsible for later abnormal neurodevelopmental prognosis, especially increase in cerebral palsy, etc (Committee on Fetus and Newborn, Pediatrics, 109: 330-8, 2002). [0004]Recently an anticipation for the treatment using stem cells having a potential to be differentiated into every organs has been rising. However, the transplantation of embryonic stem cells which have excellent differentiation potential has serious technical and ethical problems, that is generation of uncontrollable teratoma, developmental problems caused by genomic imprinting, and questions of moral and ethics. Therefore, the application of embryonic stem cells seems to be limited and instead adult stem cells have been moved into the center of our interest. [0005]Among adult stem cells, stem cells of hematopoietic system are a major target, stem cells of Hematopoietic system in bone marrow, which is their source, are generally grouped into two; hematopoietic stem cells and mesenchymal stem cells. [0006]It has been already known that the hematopoietic stem cells in bone marrow have plasticity, suggesting that they are differentiated into not only hematopoietic system cells but also other organ cells (Gussoni E, Soneoka Y et al. Nature., 401:390-394, 1999; Petersen B E et al., Science. 284:1168-1170, 1999; Mezey E et al., Science. 290:1779-1782, 2000; Krause D S et al., Cell., 105:369-377, 2001), which is though not very common so that there is a doubt of biological usefulness, and some reports that was resulted from cell fusion, not from direct differentiation (Wagers A J et al., Science., 297:2256-2259, 2002). [0007]Whereas, mesenchymal stem cells separated from bone marrow of an adult mouse, which were then named `multipotent adult progenitor cell (MAPC)` are very capable of being differentiated into all three germ layers, ectoderm, mesoderm and endoderm, and in fact they were proved when the stem cells were injected into blastocyst of a mouse to be differentiated into almost every organ cells. These cells were reported to bear embryonic stem cell markers such as OCT-4, Rex 1 and SSEA-1 (Jiang Y et al., Nature. 418:41-49, 2002). [0008]It is expected that the similar stem cells can be separated from human bone marrow to be applied to cell therapy for diseases and damages (Reyes M et al., Blood. 98:2615-2625, 2001; Woodbury D et al., J Neurosci Res., 61:364-370, 2000). However, hematopoietic stem cell and mesenchymal stem cell regions are reduced in bone marrow according to aging (Geiger H and Van Zant G. Nat Immunol., 3:329-333, 2002), and bone marrow extraction itself is distressing, which is disadvantage for actual clinical application. Thus, alternatives have been searched. [0009]Umbilical cord is the line connecting a mother and a fetus through which nutrition is provided and wastes is excreted, and the blood inside is called umbilical cord blood. The umbilical cord blood seems to be the most appropriate alternative for bone marrow for hematopoietic stem cell extraction because it contains more primitive stem cells, compared with those in bone marrow, and cell extraction therefrom is much easier. [0010]The transplantation of hematopoietic stem cells extracted from umbilical cord blood has been clinically applied since 1980s, based on such advantages, compared with bone marrow, as higher hematopoietic proliferation activity which means more hematopoietic stem cells per unit volume (Szilvassy S J et al., Blood. 98:2108-2115, 2001), less HLA incompatibility which means less graft versus host reactions (Rocha V et al., N Engl J Med., 342:1846-1854, 2000), simple and easy, and less invasive during extraction (Rubinstein P et al., N Engl J Med., 339:1565-1577, 1998) and remarkably lower risks of autologous marrow transplantation in case of various types of cancer or other diseases. In particular, umbilical cord blood bank has been opened recently, providing services of preservation and amplification of umbilical cord blood and their cells, which triggers the clinical practice for transplantation of hematopoietic stem cells of umbilical cord blood. [0011]It is controversial whether mesenchymal stem cells particularly MAPC-like cells that have excellent differentiation potential into various organ cells reside in umbilical cord blood. If mass-production of such mesenchymal stem cells or MAPC-like cells is possible from umbilical cord blood, it would be an epoch-making discovery in cell therapy and cell & tissue regenerative medicine. It has been predicted based on the primitiveness of stem cells of umbilical cord blood that MAPC-like cells exist more in umbilical cord blood than in bone marrow. Recently mesenchymal stem cells were successfully separated from umbilical cord blood (Erices A et al., Br J Haematol., 109:235-242, 2000) and further proved to have MAPC cell-level multipotency enabling the differentiation into osteoblasts, lipocytes and nerve cells ex vivo (Lee O K et al., Blood., 103:1669-1675, 2004). At first, it was a common belief that the number of mesenchymal cells to be taken from umbilical cord blood was small and the proliferation of them was very difficult. But, according to recent reports, it has been proved that umbilical cord blood can provide huge number of mesenchymal stem cells and thereby ex vivo amplification of these cells is also possible. [0012]It has been reported that these cells still possess multipotency after being amplified, and can be differentiated into osteoblasts, chondroblasts, lipocytes and nerve cells ex vivo, and nerve cells, cartilage and bone cells, hematopoietic cells and stem cells in vivo (Kogler G et al., J Exp Med., 200:123-135, 2004). [0013]Methodologically, umbilical cord blood extracted from the real placental tissue can be most ideal source for autologous and homologous stem cells and these stem cells obtained thereby can be used directly or after amplifying stage whenever and as many as required. [0014]However, there has been no attempt to apply umbilical cord blood derived stem cell transplantation to developmental and/or chronic lung disease. There are a few experimental reports that the adult bone marrow stem cells transplanted into a mouse with pneumonia induced by irradiation were differentiated into bronchial cells and type II pneumonocyte (Theise N D et al. Exp Hematol., 30:1333-1338, 2002) and reduced bleomycin induced pulmonary fibrosis in adult animal models (Ortiz L et al. Proc Natl Acad Sci USA, 100:8407-8411, 2003). [0015]There are some patents about disease treatment using the umbilical cord blood originated cells. For example, Korean Patent Publication No. 2003-0015160 describes a composition for the treatment of articular cartilage damage comprising cell components separated, proliferated and differentiated from umbilical cord blood and a medium containing thereof. And, Korean Patent Publication No. 2005-0105467 describes a method for treating myelodysplastic syndrome and myelosclerosis by the administration of umbilical cord blood-originated stem cells. However, there have been no descriptions on the therapeutic effect of umbilical cord blood-derived stem cell transplantation in developmental and/or chronic lung disease. [0016]Thus, the present inventors established bronchopulmonary dysplasia model by administering high concentrated oxygen continuously, and then administered a composition of the invention into the airway. As a result, alveoli were increased in their numbers and developed normally. In conclusion, the present inventors completed this invention by confirming that the composition of the present invention can be effectively used for the treatment of developmental and/or chronic lung disease. DISCLOSURE [Technical Problem] [0017]It is an object of the present invention to provide a composition comprising stem cells of umbilical cord blood for the treatment of developmental and/or chronic lung disease, for which no specific treatment method has been reported, yet. [Technical Solution] [0018]The present invention provides a composition for treating developmental and/or chronic lung disease comprising separated and proliferated cells from umbilical cord blood. [0019]Umbilical cord blood, the origin of therapeutic cells of the invention, is defined as blood taken from umbilical vein connecting placenta and a fetus. Umbilical cord blood is a natural by-product of childbirth. The umbilical cord blood is much easier to obtain than general mesenchymal tissue like bone marrow requiring several steps of operation and it is also very easy to find a donor because umbilical cord blood deposit industry is developing steadily and infra has already been established. In addition, umbilical cord blood-originated cells are the one that does not express histocompatibility antigen HLA-DR (class II) which is the major cause of rejection after tissue- or organ transplantation. Thus, these cells can minimize the immune response according to transplantation, for example rejection against transplanted tissue or organ, suggesting that autologous or homologous umbilical cord blood transplantation is very useful and effective. Continue reading... Full patent description for Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease patent application. Patent Applications in related categories: 20080233087 - Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin-1 gene product on adult pancreatic cells is used to identify pancreatic endocrine progenitor cells, and useful in methods of isolation and enrichment. Isolated pancreatic endocrine progenitor cells can be used for cell ... 20080233088 - Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation - The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease or other areas of interest. ### Previous Patent Application: Methods of using stable ascorbic acid compositions Next Patent Application: Methods for detecting dna damage and screening for cancer therapeutics Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Composition comprising separated or proliferated cells from umbilical cord blood for treating developmental and/or chronic lung disease patent info. IP-related news and info Results in 0.86041 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error |
||
